{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:22Z","timestamp":1792787902421,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Associazione Italiana per la Ricerca sul Cancro","award":["Fellowship - 31664"],"award-info":[{"award-number":["Fellowship - 31664"]}],"id":[{"id":"https:\/\/ror.org\/02g2x7380","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Associazione Italiana per la Ricerca sul Cancro","award":["IG-25024"],"award-info":[{"award-number":["IG-25024"]}],"id":[{"id":"https:\/\/ror.org\/02g2x7380","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Supporting Talent in ReSearch@University of Padua - Starting Grant","award":["Be_CL3EVER"],"award-info":[{"award-number":["Be_CL3EVER"]}],"id":[{"id":"https:\/\/ror.org\/00240q980","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ricerca per Credere nella Vita (RCV) odv, Padua, Italy"},{"name":"Associazione Italiana Contro le Leucemie-Linfomi e Mieloma","id":[{"id":"https:\/\/ror.org\/02st2pm23","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In chronic lymphocytic leukemia (CLL), B-cell receptor, chemokine receptor and integrin signaling contribute to disease progression by influencing cell survival, migration and microenvironment interactions. Focal adhesion kinase (FAK) has recently been involved in these disease processes. Our recent research revealed a correlation between activated FAK and molecules involved in CLL aggressiveness, particularly in IGHV-unmutated cases, including the Lyn kinase substrates HS1 and cortactin. In this context, ROR1 is a key player, sharing connections with Lyn substrates and FAK pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We assessed FAK and ROR1 bidirectional association by stimulating CLL cells with Wnt5a and measuring FAK phosphorylation by Western blot, while ROR1 expression was evaluated following FAK inhibitor treatment. Flow cytometry using CXCR4 and CD5 markers was performed to identify and sort proliferating (CXCR4\n                      <jats:sup>dim<\/jats:sup>\n                      \/CD5\n                      <jats:sup>bright<\/jats:sup>\n                      ) versus quiescent (CXCR4\n                      <jats:sup>bright<\/jats:sup>\n                      \/CD5\n                      <jats:sup>dim<\/jats:sup>\n                      ) B-cell subpopulations from CLL patients. FAK and ROR1 levels were compared between these fractions. Findings were further supported ex vivo in ibrutinib-treated patients. The FAK inhibitor defactinib was tested alone and in combination with BTK inhibitors on primary CLL cells cultured with or without stromal support, measuring apoptosis by Annexin V\/PI staining.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We demonstrated that ROR1 triggering by Wnt5a increases FAK activation, while FAK inhibition reduces ROR1 expression. Significantly higher levels of FAK and ROR1 were detected in the proliferating subpopulation corresponding to cells egressing lymph nodes compared to quiescent cells. Ex vivo experiments confirmed high FAK and ROR1 levels in circulating lymphocytes redistributing from secondary lymphoid organs. Defactinib significantly enhanced apoptosis in CLL cells when combined with BTK inhibitors, even in supportive microenvironments, showing significant efficacy also against aggressive CLLs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings reveal a reciprocal regulatory relationship between FAK and ROR1, with both proteins enriched in CLL cells that have exited the lymph nodes. Given defactinib\u2019s favorable safety profile in solid tumor trials, combining FAK inhibition with BTK inhibitors could enhance therapeutic efficacy by limiting leukemic clone adaptability and addressing resistance and relapse. While anti-ROR1 therapies showed limited efficacy as monotherapy in CLL trials, targeting multiple nodes of this regulatory network may prove more effective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-05025-1","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:58:10Z","timestamp":1782712690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Focal adhesion kinase FAK interplays with ROR1 in the aggressiveness of chronic lymphocytic leukemia"],"prefix":"10.1186","volume":"24","author":[{"given":"Maria","family":"Castronuovo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Beltrame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayla","family":"Mouawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Gramegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fantato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Angotzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Serafin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Facco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7093-2493","authenticated-orcid":false,"given":"Federica","family":"Frezzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"3","key":"5025_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajh.27546","volume":"100","author":"M Hallek","year":"2025","unstructured":"Hallek M, Chronic Lymphocytic L. 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy. Am J Hematol. 2025;100(3):450\u201380. https:\/\/doi.org\/10.1002\/ajh.27546.","journal-title":"Am J Hematol"},{"issue":"2","key":"5025_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1053\/j.seminhematol.2024.04.002","volume":"61","author":"JT Patton","year":"2024","unstructured":"Patton JT, Woyach JA. Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia. Semin Hematol. 2024;61(2):100\u20138. https:\/\/doi.org\/10.1053\/j.seminhematol.2024.04.002.","journal-title":"Semin Hematol"},{"issue":"3","key":"5025_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bbamcr.2015.07.009","volume":"1863","author":"E Ten Hacken","year":"2016","unstructured":"Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta. 2016;1863(3):401\u201313. https:\/\/doi.org\/10.1016\/j.bbamcr.2015.07.009.","journal-title":"Biochim Biophys Acta"},{"issue":"39","key":"5025_CR4","doi-asserted-by":"publisher","first-page":"42130","DOI":"10.18632\/oncotarget.6239","volume":"6","author":"V Trimarco","year":"2015","unstructured":"Trimarco V, Ave E, Facco M, et al. Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. Oncotarget. 2015;6(39):42130\u201349. https:\/\/doi.org\/10.18632\/oncotarget.6239.","journal-title":"Oncotarget"},{"issue":"2","key":"5025_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1189\/jlb.1203652","volume":"76","author":"S L\u00f3pez-Giral","year":"2004","unstructured":"L\u00f3pez-Giral S, Quintana NE, Cabrerizo M, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol. 2004;76(2):462\u201371. https:\/\/doi.org\/10.1189\/jlb.1203652.","journal-title":"J Leukoc Biol"},{"issue":"19","key":"5025_CR6","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1158\/0008-5472.CAN-15-0986","volume":"75","author":"L Patrussi","year":"2015","unstructured":"Patrussi L, Capitani N, Martini V, et al. Enhanced chemokine receptor recycling and impaired S1P1 expression promote leukemic cell infiltration of lymph nodes in Chronic Lymphocytic Leukemia. Cancer Res. 2015;75(19):4153\u201363. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0986.","journal-title":"Cancer Res"},{"issue":"22","key":"5025_CR7","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1182\/blood-2012-04-425959","volume":"120","author":"N Capitani","year":"2012","unstructured":"Capitani N, Patrussi L, Trentin L, et al. S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. Blood. 2012;120(22):4391\u20139. https:\/\/doi.org\/10.1182\/blood-2012-04-425959.","journal-title":"Blood"},{"issue":"2","key":"5025_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10637-025-01513-y","volume":"43","author":"S Gupta","year":"2025","unstructured":"Gupta S, Sharma A, Shukla A, Mishra A, Singh A. From development to clinical success: the journey of established and next-generation BTK inhibitors. Invest New Drugs. 2025;43(2):377\u201393. https:\/\/doi.org\/10.1007\/s10637-025-01513-y.","journal-title":"Invest New Drugs"},{"key":"5025_CR9","doi-asserted-by":"publisher","unstructured":"Brown JR. Resistance to Bruton Tyrosine Kinase Inhibitors. Hematol Oncol Clin North Am. 2025;11:S0889-8588(25)00081\u2009\u2013\u20094. https:\/\/doi.org\/10.1016\/j.hoc.2025.05.009","DOI":"10.1016\/j.hoc.2025.05.009"},{"issue":"3","key":"5025_CR10","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3390\/ijms23031726","volume":"23","author":"HH Chuang","year":"2022","unstructured":"Chuang HH, Zhen YY, Tsai YC, et al. FAK in cancer: from mechanisms to therapeutic strategies. Int J Mol Sci. 2022;23(3):1726. https:\/\/doi.org\/10.3390\/ijms23031726.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5025_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ceb.2006.08.011","volume":"18","author":"SK Mitra","year":"2006","unstructured":"Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18(5):516\u201323. https:\/\/doi.org\/10.1016\/j.ceb.2006.08.011.","journal-title":"Curr Opin Cell Biol"},{"issue":"4","key":"5025_CR12","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/jcmm.17688","volume":"27","author":"FV Sbrana","year":"2023","unstructured":"Sbrana FV, Fiordi B, Bordini J, et al. PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target. J Cell Mol Med. 2023;27(4):576\u201386. https:\/\/doi.org\/10.1111\/jcmm.17688.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"5025_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/bjh.18996","volume":"203","author":"F Severin","year":"2023","unstructured":"Severin F, Mouawad N, Ruggeri E, et al. Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness. Br J Haematol. 2023;203(2):224\u201336. https:\/\/doi.org\/10.1111\/bjh.18996.","journal-title":"Br J Haematol"},{"issue":"7","key":"5025_CR14","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3390\/cancers14071600","volume":"14","author":"TA Burley","year":"2022","unstructured":"Burley TA, Hesketh A, Bucca G, et al. Elucidation of Focal Adhesion Kinase as a modulator of migration and invasion and as a potential therapeutic target in Chronic Lymphocytic Leukemia. Cancers (Basel). 2022;14(7):1600. https:\/\/doi.org\/10.3390\/cancers14071600.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"5025_CR15","doi-asserted-by":"publisher","first-page":"e39902","DOI":"10.1371\/journal.pone.0039902","volume":"7","author":"F Frezzato","year":"2012","unstructured":"Frezzato F, Gattazzo C, Martini V, et al. HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen. PLoS ONE. 2012;7(6):e39902. https:\/\/doi.org\/10.1371\/journal.pone.0039902.","journal-title":"PLoS ONE"},{"issue":"6","key":"5025_CR16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3324\/haematol.2013.090183","volume":"99","author":"C Gattazzo","year":"2014","unstructured":"Gattazzo C, Martini V, Frezzato F, et al. Cortactin, another player in the Lyn signaling pathway, is over-expressed and alternatively spliced in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Haematologica. 2014;99(6):1069\u201377. https:\/\/doi.org\/10.3324\/haematol.2013.090183.","journal-title":"Haematologica"},{"issue":"1","key":"5025_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/bjh.14642","volume":"178","author":"V Martini","year":"2017","unstructured":"Martini V, Gattazzo C, Frezzato F, et al. Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. Br J Haematol. 2017;178(1):81\u201393. https:\/\/doi.org\/10.1111\/bjh.14642.","journal-title":"Br J Haematol"},{"issue":"1","key":"5025_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41420-024-02239-1","volume":"10","author":"AB Tigu","year":"2024","unstructured":"Tigu AB, Munteanu R, Moldovan C, et al. Therapeutic advances in the targeting of ROR1 in hematological cancers. Cell Death Discov. 2024;10(1):471. https:\/\/doi.org\/10.1038\/s41420-024-02239-1.","journal-title":"Cell Death Discov"},{"issue":"12","key":"5025_CR19","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1038\/leu.2017.133","volume":"31","author":"MK Hasan","year":"2017","unstructured":"Hasan MK, Yu J, Chen L, et al. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2017;31(12):2615\u201322. https:\/\/doi.org\/10.1038\/leu.2017.133.","journal-title":"Leukemia"},{"issue":"3","key":"5025_CR20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41375-018-0306-7","volume":"33","author":"MK Hasan","year":"2019","unstructured":"Hasan MK, Rassenti L, Widhopf GF 2nd, Yu J, Kipps TJ. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2019;33(3):653\u201361. https:\/\/doi.org\/10.1038\/s41375-018-0306-7.","journal-title":"Leukemia"},{"key":"5025_CR21","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1038\/srep05811","volume":"4","author":"H Zhang","year":"2014","unstructured":"Zhang H, Qiu J, Ye C, et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep. 2014;4:5811. https:\/\/doi.org\/10.1038\/srep05811.","journal-title":"Sci Rep"},{"issue":"5","key":"5025_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00428-016-1911-3","volume":"468","author":"HP Chien","year":"2016","unstructured":"Chien HP, Ueng SH, Chen SC, et al. Expression of ROR1 has prognostic significance in triple negative breast cancer. Virchows Arch. 2016;468(5):589\u201395. https:\/\/doi.org\/10.1007\/s00428-016-1911-3.","journal-title":"Virchows Arch"},{"issue":"24","key":"5025_CR23","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/bloodadvances.2017010215","volume":"1","author":"H Karvonen","year":"2017","unstructured":"Karvonen H, Chiron D, Niininen W, et al. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Adv. 2017;1(24):2257\u201368. https:\/\/doi.org\/10.1182\/bloodadvances.2017010215.","journal-title":"Blood Adv"},{"issue":"5","key":"5025_CR24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccr.2012.08.027","volume":"22","author":"VT Bicocca","year":"2012","unstructured":"Bicocca VT, Chang BH, Masouleh BK, et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 2012;22(5):656\u201367. https:\/\/doi.org\/10.1016\/j.ccr.2012.08.027.","journal-title":"Cancer Cell"},{"issue":"9","key":"5025_CR25","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14(9):598\u2013610. https:\/\/doi.org\/10.1038\/nrc3792.","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"5025_CR26","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.3390\/cancers13215453","volume":"13","author":"F Frezzato","year":"2021","unstructured":"Frezzato F, Visentin A, Severin F, et al. Targeting of HSP70\/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia. Cancers (Basel). 2021;13(21):5453. https:\/\/doi.org\/10.3390\/cancers13215453.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"5025_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bjh.12815","volume":"165","author":"F Frezzato","year":"2014","unstructured":"Frezzato F, Trimarco V, Martini V, et al. Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole. Br J Haematol. 2014;165(5):659\u201372. https:\/\/doi.org\/10.1111\/bjh.12815.","journal-title":"Br J Haematol"},{"issue":"5","key":"5025_CR28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1189\/jlb.2AB0715-301R","volume":"100","author":"F Frezzato","year":"2016","unstructured":"Frezzato F, Accordi B, Trimarco V, et al. Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins. J Leukoc Biol. 2016;100(5):1061\u201370. https:\/\/doi.org\/10.1189\/jlb.2AB0715-301R.","journal-title":"J Leukoc Biol"},{"issue":"5","key":"5025_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00424-015-1780-7","volume":"468","author":"L Baki","year":"2016","unstructured":"Baki L, Fribourg M, Younkin J, et al. Cross-signaling in metabotropic glutamate 2 and serotonin 2A receptor heteromers in mammalian cells. Pflugers Arch. 2016;468(5):775\u201393.","journal-title":"Pflugers Arch"},{"issue":"3","key":"5025_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2012.01.015","volume":"36","author":"RR Rao","year":"2012","unstructured":"Rao RR, Li Q, Gubbels Bupp MR, et al. Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8(+) T cell differentiation. Immunity. 2012;36(3):374\u201387.","journal-title":"Immunity"},{"issue":"6085","key":"5025_CR31","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1126\/science.1213368","volume":"336","author":"AM Khalil","year":"2012","unstructured":"Khalil AM, Cambier JC, Shlomchik MJ. B cell receptor signal transduction in the GC is short-circuited by high phosphatase activity. Science. 2012;336(6085):1178\u201381.","journal-title":"Science"},{"issue":"14","key":"5025_CR32","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood.2021014760","volume":"140","author":"TJ Kipps","year":"2022","unstructured":"Kipps TJ. ROR1: an orphan becomes apparent. Blood. 2022;140(14):1583\u201391. https:\/\/doi.org\/10.1182\/blood.2021014760.","journal-title":"Blood"},{"key":"5025_CR33","doi-asserted-by":"publisher","unstructured":"Calissano C, Damle RN, Marsilio S et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born\/divided and older\/quiescent cells. Mol Med. 2011;17(11\u201312):1374-82. doi: 10.2119\/molmed.2011.00360. Erratum in: Mol Med. 2022;28(1):35. https:\/\/doi.org\/10.1186\/s10020-022-00461-0","DOI":"10.1186\/s10020-022-00461-0"},{"issue":"6","key":"5025_CR34","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1097\/HS9.0000000000000722","volume":"6","author":"K Kluckova","year":"2022","unstructured":"Kluckova K, Clear AJ, D\u2019Avola A, et al. B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities. Hemasphere. 2022;6(6):e722. https:\/\/doi.org\/10.1097\/HS9.0000000000000722.","journal-title":"Hemasphere"},{"issue":"26","key":"5025_CR35","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1182\/blood-2014-02-554220","volume":"123","author":"D Wodarz","year":"2014","unstructured":"Wodarz D, Garg N, Komarova NL, Benjamini O, et al. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014;123(26):4132\u20135. https:\/\/doi.org\/10.1182\/blood-2014-02-554220.","journal-title":"Blood"},{"issue":"21","key":"5025_CR36","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.3390\/cancers15215160","volume":"15","author":"M Cerreto","year":"2023","unstructured":"Cerreto M, Fo\u00e0 R, Natoni A. The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia. Cancers (Basel). 2023;15(21):5160. https:\/\/doi.org\/10.3390\/cancers15215160.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"5025_CR37","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s11864-025-01339-z","volume":"26","author":"PV Shah","year":"2025","unstructured":"Shah PV, Gladstone DE, Covalent, Non-Covalent BTK. Inhibition in Chronic Lymphocytic Leukemia Treatment. Curr Treat Options Oncol. 2025;26(8):754\u201363. https:\/\/doi.org\/10.1007\/s11864-025-01339-z.","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"5025_CR38","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.3390\/cancers11121939","volume":"11","author":"F Severin","year":"2019","unstructured":"Severin F, Frezzato F, Visentin A, et al. In Chronic Lymphocytic Leukemia the JAK2\/STAT3 pathway is constitutively activated and its inhibition leads to CLL cell death unaffected by the protective bone marrow microenvironment. Cancers (Basel). 2019;11(12):1939. https:\/\/doi.org\/10.3390\/cancers11121939.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"5025_CR39","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.3324\/haematol.2018.209981","volume":"104","author":"L Patrussi","year":"2019","unstructured":"Patrussi L, Capitani N, Ulivieri C, et al. p66Shc deficiency in the E\u00b5-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape. Haematologica. 2019;104(10):2040\u201352. https:\/\/doi.org\/10.3324\/haematol.2018.209981.","journal-title":"Haematologica"},{"issue":"12","key":"5025_CR40","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","volume":"34","author":"JA Burger","year":"2013","unstructured":"Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34(12):592\u2013601. https:\/\/doi.org\/10.1016\/j.it.2013.07.002.","journal-title":"Trends Immunol"},{"issue":"2","key":"5025_CR41","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","volume":"117","author":"Y Herishanu","year":"2011","unstructured":"Herishanu Y, P\u00e9rez-Gal\u00e1n P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563\u201374. https:\/\/doi.org\/10.1182\/blood-2010-05-284984.","journal-title":"Blood"},{"issue":"7","key":"5025_CR42","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1158\/0008-5472.CAN-08-4136","volume":"69","author":"TN Hartmann","year":"2009","unstructured":"Hartmann TN, Grabovsky V, Wang W, et al. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. Cancer Res. 2009;69(7):3121\u201330. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4136.","journal-title":"Cancer Res"},{"issue":"9","key":"5025_CR43","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1158\/0008-5472.CAN-08-4173","volume":"69","author":"A Zucchetto","year":"2009","unstructured":"Zucchetto A, Benedetti D, Tripodo C, et al. CD38\/CD31, the CCL3 and CCL4 chemokines, and CD49d\/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res. 2009;69(9):4001\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4173.","journal-title":"Cancer Res"},{"issue":"2","key":"5025_CR44","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1172\/JCI22094","volume":"115","author":"A Contri","year":"2005","unstructured":"Contri A, Brunati AM, Trentin L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005;115(2):369\u201378. https:\/\/doi.org\/10.1172\/JCI22094.","journal-title":"J Clin Invest"},{"issue":"12","key":"5025_CR45","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1182\/blood-2008-02-139139","volume":"112","author":"L Trentin","year":"2008","unstructured":"Trentin L, Frasson M, Donella-Deana A, et al. Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood. 2008;112(12):4665\u201374. https:\/\/doi.org\/10.1182\/blood-2008-02-139139.","journal-title":"Blood"},{"key":"5025_CR46","doi-asserted-by":"publisher","first-page":"838871","DOI":"10.3389\/fcell.2022.838871","volume":"10","author":"Z Dave","year":"2022","unstructured":"Dave Z, Vond\u00e1lov\u00e1 Blan\u00e1\u0159ov\u00e1 O, \u010cada \u0160, et al. Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells. Front Cell Dev Biol. 2022;10:838871. https:\/\/doi.org\/10.3389\/fcell.2022.838871.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"5025_CR47","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41388-017-0066-2","volume":"37","author":"L Patrussi","year":"2018","unstructured":"Patrussi L, Capitani N, Cattaneo F, et al. p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from \u03b2-arrestin at early endosomes. Oncogene. 2018;37(11):1534\u201350. https:\/\/doi.org\/10.1038\/s41388-017-0066-2.","journal-title":"Oncogene"},{"issue":"13","key":"5025_CR48","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1182\/blood.2019001366","volume":"134","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chen L, Yu J, et al. Cirmtuzumab blocks Wnt5a\/ROR1 stimulation of NF-\u03baB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019;134(13):1084\u201394. https:\/\/doi.org\/10.1182\/blood.2019001366.","journal-title":"Blood"},{"issue":"6","key":"5025_CR49","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-16-0719","volume":"16","author":"BZ Carter","year":"2017","unstructured":"Carter BZ, Mak PY, Wang X, et al. Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther. 2017;16(6):1133\u201344. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0719.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"5025_CR50","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1158\/0008-5472.CAN-15-2137","volume":"76","author":"A Budina-Kolomets","year":"2016","unstructured":"Budina-Kolomets A, Webster MR, Leu JI, et al. HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res. 2016;76(9):2720\u201330. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2137.","journal-title":"Cancer Res"},{"issue":"11","key":"5025_CR51","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1002\/ijc.32383","volume":"145","author":"F Frezzato","year":"2019","unstructured":"Frezzato F, Raggi F, Martini V, et al. HSP70\/HSF1 axis, regulated via a PI3K\/AKT pathway, is a druggable target in chronic lymphocytic leukemia. Int J Cancer. 2019;145(11):3089\u2013100. https:\/\/doi.org\/10.1002\/ijc.32383.","journal-title":"Int J Cancer"},{"issue":"8","key":"5025_CR52","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41419-022-05172-2","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, He Z, Liu X, et al. LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2. Cell Death Dis. 2022;13(8):718. https:\/\/doi.org\/10.1038\/s41419-022-05172-2.","journal-title":"Cell Death Dis"},{"issue":"5","key":"5025_CR53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/ajh.21381","volume":"84","author":"Y Le","year":"2009","unstructured":"Le Y, Xu L, Lu J, et al. FAK silencing inhibits leukemogenesis in BCR\/ABL-transformed hematopoietic cells. Am J Hematol. 2009;84(5):273\u20138. https:\/\/doi.org\/10.1002\/ajh.21381.","journal-title":"Am J Hematol"},{"issue":"4","key":"5025_CR54","doi-asserted-by":"publisher","first-page":"e86082","DOI":"10.1172\/jci.insight.86082","volume":"1","author":"ML Churchman","year":"2016","unstructured":"Churchman ML, Evans K, Richmond J, et al. Synergism of FAK and tyrosine kinase inhibition in Ph\u2009+\u2009B-ALL. JCI Insight. 2016;1(4):e86082. https:\/\/doi.org\/10.1172\/jci.insight.86082.","journal-title":"JCI Insight"},{"key":"5025_CR55","doi-asserted-by":"publisher","first-page":"1446723","DOI":"10.3389\/fonc.2024.1446723","volume":"14","author":"G Capasso","year":"2024","unstructured":"Capasso G, Mouawad N, Castronuovo M, et al. Focal adhesion kinase as a new player in the biology of onco-hematological diseases: the starting evidence. Front Oncol. 2024;14:1446723. https:\/\/doi.org\/10.3389\/fonc.2024.1446723.","journal-title":"Front Oncol"},{"issue":"12","key":"5025_CR56","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1038\/leu.2017.132","volume":"31","author":"J Yu","year":"2017","unstructured":"Yu J, Chen L, Chen Y, et al. Wnt5a induces ROR1 to associate with 14-3-3\u03b6 for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017;31(12):2608\u201314. https:\/\/doi.org\/10.1038\/leu.2017.132.","journal-title":"Leukemia"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05025-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05025-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05025-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:18:00Z","timestamp":1789521480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05025-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5025"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05025-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, with written informed consent obtained from all participants and ethical approval granted by the local ethics committee (approval number: 4839\/AO\/20).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"496"}}